Intercure (INCR) - Net Assets
Based on the latest financial reports, Intercure (INCR) has net assets worth ILA396.36 Million ILA (≈ $1.06 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (ILA690.55 Million ≈ $1.85 Million USD) and total liabilities (ILA294.19 Million ≈ $788.73K USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Intercure tangible book value ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ILA396.36 Million |
| % of Total Assets | 57.4% |
| Annual Growth Rate | N/A |
| 5-Year Change | -13.68% |
| 10-Year Change | 1546.81% |
| Growth Volatility | 516.61 |
Intercure - Net Assets Trend (2008–2025)
This chart illustrates how Intercure's net assets have evolved over time, based on quarterly financial data. See INCR defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Intercure (2008–2025)
The table below shows the annual net assets of Intercure from 2008 to 2025. For live valuation and market cap data, see market value of Intercure.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | ILA396.36 Million ≈ $1.06 Million |
-0.33% |
| 2024-12-31 | ILA397.67 Million ≈ $1.07 Million |
-12.99% |
| 2023-12-31 | ILA457.06 Million ≈ $1.23 Million |
-12.35% |
| 2022-12-31 | ILA521.48 Million ≈ $1.40 Million |
+13.56% |
| 2021-12-31 | ILA459.19 Million ≈ $1.23 Million |
+57.20% |
| 2020-12-31 | ILA292.11 Million ≈ $783.13K |
+14.02% |
| 2019-12-31 | ILA256.20 Million ≈ $686.87K |
+1203.03% |
| 2018-12-31 | ILA19.66 Million ≈ $52.71K |
-4.92% |
| 2017-12-31 | ILA20.68 Million ≈ $55.44K |
-14.08% |
| 2016-12-31 | ILA24.07 Million ≈ $64.53K |
+101.36% |
| 2015-12-31 | ILA11.95 Million ≈ $32.05K |
+1614.89% |
| 2014-12-31 | ILA697.01K ≈ $1.87K |
-82.21% |
| 2013-12-31 | ILA3.92 Million ≈ $10.50K |
-60.17% |
| 2012-12-31 | ILA9.84 Million ≈ $26.37K |
+119.02% |
| 2011-12-31 | ILA-51.72 Million ≈ $-138.66K |
-329.82% |
| 2010-12-31 | ILA-12.03 Million ≈ $-32.26K |
-41.30% |
| 2009-12-31 | ILA-8.52 Million ≈ $-22.83K |
+55.79% |
| 2008-12-31 | ILA-19.26 Million ≈ $-51.64K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Intercure's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 14759630200.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | ILA675.60 Million | 170.38% |
| Other Comprehensive Income | ILA15.95 Million | 4.02% |
| Other Components | ILA19.59 Million | 4.94% |
| Total Equity | ILA396.52 Million | 100.00% |
Intercure Competitors by Market Cap
The table below lists competitors of Intercure ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
FRIWO AG
F:CEA
|
$39.01 Million |
|
Respiri Ltd
AU:RSH
|
$39.01 Million |
|
Culp, Inc. Common Stock
NASDAQ:CULP
|
$39.02 Million |
|
Enjoei S.A
SA:ENJU3
|
$39.02 Million |
|
TPBI PCL
BK:TPBI
|
$38.98 Million |
|
Diatreme Resources Ltd
AU:DRX
|
$38.98 Million |
|
Minehub Technologies Inc
V:MHUB
|
$38.97 Million |
|
Jacques Bogart SA
PA:JBOG
|
$38.97 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Intercure's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 396,969,000 to 396,521,000, a change of -448,000 (-0.1%).
- Net loss of 35,710,000 reduced equity.
- New share issuances of 1,500,000 increased equity.
- Other factors increased equity by 33,762,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ILA-35.71 Million | -9.01% |
| Share Issuances | ILA1.50 Million | +0.38% |
| Other Changes | ILA33.76 Million | +8.51% |
| Total Change | ILA- | -0.11% |
Book Value vs Market Value Analysis
This analysis compares Intercure's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 38.10x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-12-31 | ILA-176.07 | ILA266.00 | x |
| 2012-12-31 | ILA22.52 | ILA266.00 | x |
| 2013-12-31 | ILA2.59 | ILA266.00 | x |
| 2014-12-31 | ILA0.43 | ILA266.00 | x |
| 2015-12-31 | ILA1.35 | ILA266.00 | x |
| 2016-12-31 | ILA1.87 | ILA266.00 | x |
| 2017-12-31 | ILA1.21 | ILA266.00 | x |
| 2018-12-31 | ILA0.95 | ILA266.00 | x |
| 2019-12-31 | ILA10.99 | ILA266.00 | x |
| 2020-12-31 | ILA10.81 | ILA266.00 | x |
| 2021-12-31 | ILA10.97 | ILA266.00 | x |
| 2022-12-31 | ILA11.05 | ILA266.00 | x |
| 2023-12-31 | ILA9.99 | ILA266.00 | x |
| 2024-12-31 | ILA8.71 | ILA266.00 | x |
| 2025-12-31 | ILA6.98 | ILA266.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Intercure utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -9.01%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -13.22%
- • Asset Turnover: 0.39x
- • Equity Multiplier: 1.74x
- Recent ROE (-9.01%) is above the historical average (-28.12%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 0.00% | -56.35% | 4.13x | 0.00x | ILA-1.63 Million |
| 2012 | 441.63% | 512.95% | 0.58x | 1.48x | ILA42.46 Million |
| 2013 | -168.61% | -80.07% | 1.34x | 1.57x | ILA-7.00 Million |
| 2014 | -544.18% | -67.13% | 2.14x | 3.79x | ILA-3.86 Million |
| 2015 | -15.71% | -134.05% | 0.11x | 1.06x | ILA-3.07 Million |
| 2016 | 1.10% | 0.00% | 0.00x | 1.15x | ILA-2.14 Million |
| 2017 | -25.43% | 0.00% | 0.00x | 1.16x | ILA-7.33 Million |
| 2018 | -65.09% | 0.00% | 0.00x | 1.83x | ILA-14.76 Million |
| 2019 | -2.30% | -66.02% | 0.03x | 1.10x | ILA-31.49 Million |
| 2020 | -13.56% | -57.25% | 0.20x | 1.19x | ILA-64.68 Million |
| 2021 | 1.05% | 2.13% | 0.32x | 1.53x | ILA-40.11 Million |
| 2022 | 8.94% | 11.53% | 0.41x | 1.91x | ILA-5.31 Million |
| 2023 | -13.61% | -17.43% | 0.45x | 1.73x | ILA-107.47 Million |
| 2024 | -17.08% | -28.38% | 0.31x | 1.92x | ILA-107.49 Million |
| 2025 | -9.01% | -13.22% | 0.39x | 1.74x | ILA-75.36 Million |
Industry Comparison
This section compares Intercure's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $5,811,624,827
- Average return on equity (ROE) among peers: 27.78%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Intercure (INCR) | ILA396.36 Million | 0.00% | 0.74x | $39.00 Million |
| Canzon Israel Ltd (CNZN) | $11.02 Million | -7.32% | 0.37x | $1.71 Million |
| Intelicanna Ltd (INTL) | $33.29 Billion | 2.45% | 0.22x | $7.78 Million |
| Kamada (KMDA) | $66.74 Million | -10.09% | 0.49x | $327.07 Million |
| Nextage Therapeutics Ltd (NXTG) | $3.66 Million | -57.11% | 0.64x | $5.79 Million |
| Rekah Pharmaceutical Industry Ltd (REKA) | $63.78 Million | 0.61% | 3.51x | $32.59 Million |
| Seach Medical Group Ltd (SEMG) | $25.69 Million | 31.20% | 0.30x | $22.21 Million |
| Teva Pharmaceutical Industries Ltd (TEVA) | $18.75 Billion | -86.77% | 2.77x | $1.23 Billion |
| Together Startup Network Ltd (TGTR) | $549.00K | 387.98% | 0.54x | $8.47 Million |
| Tikun Olam Cannbit Pharmaceuticals Ltd (TKUN) | $99.87 Million | -10.90% | 0.56x | $28.21 Million |
About Intercure
InterCure Ltd., together with its subsidiaries, engages in the production, manufacturing, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil. It also invests in the biomed sector. The company was incorporated in 1994 and is headquartered in… Read more